L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with peg interferon-α 2b plus ribavirin

World Journal of Gastroenterology

Volumn 17, Issue 39, 2011, Pages 4414-4420

  Malaguarnera, Michele ^b   Vacante, Marco ^b   Giordano, Maria ^b   Motta, Massimo ^b   Bertino, Gaetano ^b   Pennisi, Manuela ^b   Neri, Sergio ^b   Malaguarnera, Mariano ^a,b   Volti, Giovanni Li ^b   Galvano, Fabio ^b  

^a Ospedale Canniz zaro   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anemia; Chronic hepatitis C; Interferon; L carnitine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARNITINE; HEMOGLOBIN; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA;

EID: 81755188299     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i39.4414     Document Type: Article

References (48)

1. Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato B. Interferon-a Treatment in Patients with Chronic Hepatitis C: A Meta-Analytic Evaluation. Clinical Drug Investigation 1995; 9: 141-149
2. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Restuccia N, Trovato BA. Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha. Ann Med 1998; 30: 213-217
3. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93-97
4. Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castori-na M, Guccione N, Rampello L. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 273-278
5. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001; 92: 1664-1668
6. Poynard T, Massard J, Rudler M, Varaud A, Lebray P, Mous-salli J, Munteanu M, Ngo Y, Thabut D, Benhamou Y, Ratziu V. Impact of interferon-alpha treatment on liver fbrosis in patients with chronic hepatitis B: an overview of published trials. Gastroenterol Clin Biol 2009; 33: 916-922
7. Malaguarnera M, Vicari E, Calogero A, Cammalleri L, Di Fazio I, Gargante MP, Pennisi G, Risino C, Ranno S, Rampello L. Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin. J Interferon Cytokine Res 2008; 28: 603-609
8. Malaguarnera M, Restuccia S, Di Fazio I, Zoccolo AM, Ferlito L, Bentivegna P. Serum carnitine levels in chronic hepatitis C patients before and after lymphoblastoid interferon-alpha treatment. BioDrugs 1999; 12: 65-69
9. Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguarnera M. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology 2003; 47: 94-97
10. Romano M, Vacante M, Cristaldi E, Colonna V, Gargante MP, Cammalleri L, Malaguarnera M. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci 2008; 53: 1114-1121
11. Campos Y, Huertas R, Bautista J, Gutiérrez E, Aparicio M, Lorenzo G, Segura D, Villanueva M, Cabello A, Alesso L. Muscle carnitine defciency and lipid storage myopathy in patients with mitochondrial myopathy. Muscle Nerve 1993; 16: 778-781
12. Weinhandl ED, Rao M, Gilbertson DT, Collins AJ, Pereira BJ. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003. Am J Kidney Dis 2007; 50: 803-812
13. Matsumoto Y, Amano I, Hirose S, Tsuruta Y, Hara S, Murata M, Imai T. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif 2001; 19: 24-32
14. Sotirakopoulos N, Athanasiou G, Tsitsios T, Mavromatidis K. The infuence of l-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD. Ren Fail 2002; 24: 505-510
15. Abdallah Y, Gligorievski D, Kasseckert SA, Dieterich L, Schäfer M, Kuhlmann CR, Noll T, Sauer H, Piper HM, Schäfer C. The role of poly (ADP-ribose) polymerase (PARP) in the autonomous proliferative response of endothelial cells to hypoxia. Cardiovasc Res 2007; 73: 568-574
16. Izgüt-Uysal VN, Agaç A, Karadogan I, Derin N. Peritoneal macrophages function modulation by L-carnitine in aging rats. Aging Clin Exp Res 2004; 16: 337-341
17. Saluk-Juszczak J, Olas B, Wachowicz B, Glowacki R, Bald E. L-carnitine modulates blood platelet oxidative stress. Cell Biol Toxicol 2010; 26: 355-365
18. Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association declaration of Helsinki. J Med Liban 1994; 42: 88-89
19. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 2259-2266
20. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324
21. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435
22. Malaguarnera M, Di Fazio I, Trovato BA, Pistone G, Maz-zoleni G. Alpha-interferon (IFN-alpha) treatment of chronic hepatitis C: analysis of some predictive factors for the response. Int J Clin Pharmacol Ther 2001; 39: 239-245
23. Thangasamy T, Subathra M, Sittadjody S, Jeyakumar P, Joyee AG, Mendoza E, Chinnakkanu P. Role of L-carnitine in the modulation of immune response in aged rats. Clin Chim Acta 2008; 389: 19-24
24. Juliet PA, Balasubramaniam D, Balasubramaniam N, Pan-neerselvam C. Carnitine: a neuromodulator in aged rats. J Gerontol A Biol Sci Med Sci 2003; 58: 970-974
25. Abd-Allah AR, Al-Majed AA, Al-Yahya AA, Fouda SI, Al-Shabana OA. L-Carnitine halts apoptosis and myelosuppres-sion induced by carboplatin in rat bone marrow cell cultures (BMC). Arch Toxicol 2005; 79: 406-413
26. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-250
27. Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stornaiuolo G, Stanzione M, Ascione T, De Sena R, Campa-none A, Filice G, Piccinino F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1633-1639
28. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244
29. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593
30. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499
31. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P, Bacca D, Fruttaldo L, Mongiò F, Francavilla R, Scotto G, Grisorio B, Calleri G, Annese M, Barelli A, Roc-chetto P, Rizzo G, Gualandi G, Poltronieri I, Barbarini G. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999; 107: 112-118
32. Reuter SE, Faull RJ, Ranieri E, Evans AM. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrol Dial Transplant 2009; 24: 990-996
33. Di Fazio I, Motta M, Musumeci S, Neri S, Pistone G, Malaguarnera M. Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C. J Interferon Cytokine Res 2004; 24: 594-599
34. El-Beshlawy A, El Accaoui R, Abd El-Sattar M, Gamal El-Deen MH, Youssry I, Shaheen N, Hamdy M, El-Ghamrawy M, Taher A. Effect of L-carnitine on the physical ftness of thalassemic patients. Ann Hematol 2007; 86: 31-34
35. Yeşilipek MA, Yeǧin O. Interferon-alpha therapy for refractory idiopathic thrombocytopenic purpura in children. Turk J Pediatr 1997; 39: 173-176
36. Palmieri L, Ronca F, Malengo S, Bertelli A. Protection of beta-thalassaemic erythrocytes from oxidative stress by pro-pionyl carnitine. Int J Tissue React 1994; 16: 121-129
37. Meral A, Tuncel P, Sürmen-Gür E, Ozbek R, Oztürk E, Günay U. Lipid peroxidation and antioxidant status in beta-thalassemia. Pediatr Hematol Oncol 2000; 17: 687-693
38. Al-Quobaili FA, Abou Asali IE. Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major. Saudi Med J 2004; 25: 871-875
39. Trovato GM, Ginardi V, Di Marco V, Dellaira AE, Corsi M. Long-term l-carnitine treatment of chronic anemia of patients with end-stage renal disease. Curr Ther Res Clin Exp 1982; 31: 1042-1049
40. Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Mura-moto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 1996; 72: 574-578
41. Watanabe H, Kobayashi A, Hayashi H, Yamazaki N. Effects of long-chain acyl carnitine on membrane fluidity of human erythrocytes. Biochim Biophys Acta 1989; 980: 315-318
42. Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin Nephrol 1999; 52: 239-245
43. Sener G, Ekşioǧlu-Demiralp E, Cetiner M, Ercan F, Sirvanci S, Gedik N, Yeǧen BC. L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol 2006; 22: 47-60
44. Franceschi C, Cossarizza A, Troiano L, Salati R, Monti D. Immunological parameters in aging: studies on natural immunomodulatory and immunoprotective substances. Int J Clin Pharmacol Res 1990; 10: 53-57
45. Bonomini M, Sirolli V, Dottori S, Amoroso L, Di Liberato L, Arduini A. L-carnitine inhibits a subset of platelet activation responses in chronic uraemia. Nephrol Dial Transplant 2007; 22: 2623-2629
46. Michno A, Raszeja-Specht A, Jankowska-Kulawy A, Pawelc-zyk T, Szutowicz A. Effect of L-carnitine on acetyl-CoA content and activity of blood platelets in healthy and diabetic persons. Clin Chem 2005; 51: 1673-1682
47. Pignatelli P, Lenti L, Sanguigni V, Frati G, Simeoni I, Gazza-niga PP, Pulcinelli FM, Violi F. Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress. Am J Physiol Heart Circ Physiol 2003; 284: H41-H48
48. Triggiani M, Oriente A, Golino P, Gentile M, Battaglia C, Brevetti G, Marone G Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine. Biochem Pharmacol 1999; 58: 1341-1348